Relapsing DLBCL Patients Seen to Respond to Farydak in Phase 2 Trial
News
Some patients with relapsed diffuse large B-cell lymphoma (DLBCL) may markedly benefit from treatment with Farydak (panobinostat), an oral drug that targets histone-modifying enzymes, according to the results of a Phase ... Read more